Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 5Sarcoma 1Myeloid 1CNS 1

Conditions

Sinonasal undifferentiated carcinoma 1Esthesioneuroblastoma, Olfactory 1Chondrosarcoma 1

Interventions

Temozolomide 31Magnetic Resonance Spectroscopy 31Specimen Handling 18Radiation 13Radiotherapy 12Biopsy 11Bevacizumab 11Nivolumab 9X-Rays 7Radiosurgery 7Nuclear Medicine Department, Hospital 7Carboplatin 7Lomustine 6Cyclophosphamide 6Vincristine 5Phantoms, Imaging 5Cisplatin 5ulixertinib 4trametinib 4pembrolizumab 4erdafitinib 4binimetinib 4abemaciclib 4Irinotecan 4Ipilimumab 4Immunoglobulin G 4Etoposide 4Disulfides 4Aminolevulinic Acid 4AZD 6244 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
enasidenib × CNS × 30 days × Clear all
NCT06176989 2026-06-03

Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
40 enrolled
CNSSarcoma

Sinonasal undifferentiated carcinoma, Chondrosarcoma, Esthesioneuroblastoma, Olfactory

Data powered by HemOnc (CC BY 4.0) Colophon âš¡